A prospective study of 123I-labeled monoclonal antibody imaging in ovarian cancer.

  title={A prospective study of 123I-labeled monoclonal antibody imaging in ovarian cancer.},
  author={Maria Granowska and Keith E. Britton and John H. Shepherd and Cyril C. Nimmon and Stephen John Mather and Bruce G. Ward and Raymond J Osborne and Maurice L. Slevin},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={4 5},
Thirty patients presenting with a pelvic mass were entered into a prospective study on the use of radioimmunoscintigraphy with the 123I-labeled monoclonal antibody HMFG2. The imaging data was obtained without knowledge of the clinical data and compared with subsequent surgical findings. A false-positive diagnosis of ovarian cancer was made in five of ten patients subsequently shown not to have ovarian cancer; thus the technique cannot be used as a screening test. A true-positive diagnosis was… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 12 extracted citations

Clinical Use of Antibodies

Developments in Nuclear Medicine • 1991
View 8 Excerpts
Highly Influenced

Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status.

Journal of controlled release : official journal of the Controlled Release Society • 2016
View 1 Excerpt

Satumomab Pendetide

Clinical Immunotherapeutics • 2012

Similar Papers

Loading similar papers…